A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma

被引：1

作者：

Kotb, Rami ^{[1
]}

Gul, Engin ^{[2
]}

Reece, Donna E. ^{[3
,4
]}

机构：

[1] Canc Care Manitoba, Winnipeg, MB, Canada

[2] Canadian Myeloma Res Grp, Toronto, ON, Canada

[3] Canadian Myeloma Res Grp Formerly MCRN, Toronto, ON, Canada

[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-15363

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4767

引用

页数：3

共 50 条

[41] Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
van Duin, Mark
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broijl, Annemiek
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[42] Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Papaiakovou, Evangelos Eleutherakis
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)
Perrot, Aurore
Lauwers-Cances, Valerie
Touzeau, Cyrille
Decaux, Olivier
Hulin, Cyrille
Macro, Magaret
Stoppa, Anne-Marie
Chretien, Marie Lorraine
Karlin, Lionel
Mariette, Clara
Jacquet, Caroline
Roussel, Murielle
Guillemot, Coralie
Devlamynck, Laure
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
BLOOD, 2021, 138
[44] A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation
Ocio, Enrique M.
Bringhen, Sara
Oliva, Stefania
Rodriguez-Otero, Paula
Kanagavel, Dheepak
Oprea, Corina
Wei, Vivian
Doroumian, Severine
Martinez-Lopez, Joaquin
BLOOD, 2017, 130
[45] Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
O'Gorman, Peter
Laubach, Jacob P.
O'Dwyer, Michael E.
Krawczyk, Janusz
Yee, Andrew J.
Gilligan, Oonagh
Cahill, Mary R.
Rosenblatt, Jacalyn
Quinn, John
Murphy, Philip T.
DiPietro, Heidi
Perera, Meegahage Ratnakanthi
Crotty, Gerard M.
Cummings, Kristen
Hayden, Patrick J.
Browne, Paul
Savell, Alexandra
O'Leary, Hilary M.
O'Keeffe, Denis
Masone, Kelly
Hennessy, Brian J.
Garcia, Thomas Guerrero
Scott, Kathleen
Saeed, Khalid
Bianchi, Giada
Dowling, Paul
Tierney, Ciara
Richardson, Paul G.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) : 562 - 573
[46] Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma
Yoshihara, Satoshi
Yoshihara, Kyoko
Shimizu, Yoshifumi
Imado, Takehito
Takatsuka, Hiroyuki
Kawamoto, Hiroyuki
Misawa, Mahito
Ifuku, Hideki
Ohe, Yokiko
Okada, Masaya
Fujimori, Yoshihiro
HEMATOLOGY, 2021, 26 (01) : 388 - 392
[47] Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
Facon, Thierry
Dimopoulos, Meletios Athanasios
Leleu, Xavier P.
Beksac, Meral
Pour, Ludek
Hajek, Roman
Liu, Zhuogang
Minarik, Jiri
Moreau, Philippe
Romejko-Jarosinska, Joanna
Spicka, Ivan
Vorobyev, Vladimir I.
Cavo, Michele
Goldschmidt, Hartmut
Martin, Thomas G.
Manier, Salomon
Bregeault, Marie-France
Mace, Sandrine
Berthou, Christelle
Orlowski, Robert Z.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients
Gay, Francesca
Roeloffzen, Wilfried
Dimopoulos, Meletios A.
Rosinol, Laura
van der Klift, Marjolein
Mina, Roberto
Oriol Rocafiguera, Albert
Katodritou, Eirini
Wu, Ka Lung
Rodriguez Otero, Paula
Hajek, Roman
Antonioli, Elisabetta
van Duin, Mark
D'Agostino, Mattia
Martinez-Lopez, Joaquin
van Leeuwen-Segarceanu, Elena M.
Tacchetti, Paola
van de Donk, Niels W. C. J.
Weisel, Katja
Pour, Ludek
Radocha, Jakub
Belotti, Angelo
Schjesvold, Fredrik
Blade, Joan
Einsele, Hermann
Sonneveld, Pieter
Boccadoro, Mario
Broijl, Annemiek
BLOOD, 2023, 142
[49] Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
Leleu, Xavier P.
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Manier, Salomon
Perrot, Aurore
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Laribi, Kamel
Chretien, Marie-Lorraine
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Chretien, Marie-Lorraine
Karlin, Lionel
Decaux, Olivier
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Planche, Lucie
Avet-Loiseau, Herve
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S25 - S25

← 1 2 3 4 5 →